Shield Therapeutics plc filed its Annual on May 19, 2023 for the period ending Dec 31, 2022. In this report its auditor, Mazars, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.85 GBX | -7.50% | +19.35% | -72.39% |
10/05 | Shield Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
30/04 | EARNINGS AND TRADING: Software Circle & Beximco report higher revenue | AN |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-72.39% | 1.97Cr | |
+7.37% | 11TCr | |
+11.28% | 11TCr | |
-12.70% | 2.22TCr | |
+0.44% | 2.13TCr | |
-4.18% | 1.9TCr | |
-37.85% | 1.85TCr | |
-8.57% | 1.68TCr | |
+37.11% | 1.25TCr | |
-24.10% | 808.97Cr |
- Stock Market
- Equities
- STX Stock
- News Shield Therapeutics plc
- Shield Therapeutics plc Auditor Raises 'Going Concern' Doubt